SCHEMBL7592082

SCHEMBL7592082

CCn1c2ccccc2c2cc(C(=O)C=Cc3cc(OC)ccc3OC)ccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.61
MAPT P10636 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
KDM4E B2RXH2 3/20 0.55
LMNA P02545 3/20 0.55
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
POLB P06746 2/20 0.53
MAOB P27338 1/20 0.51
ALDH1A1 P00352 4/20 0.50
RAB9A P51151 4/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HCRTR1 O43613 2/20 0.50
HPGD P15428 2/20 0.50
NPC1 O15118 2/20 0.50
RELA Q04206 2/20 0.50
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7591200 0.92 MAPT (0.60) ABCG2MAPTSMN1; SMN2KDM4ELMNA
SCHEMBL7588249 0.90 MAPT (0.55) MAPTSMN1; SMN2KDM4ELMNAPOLB
SCHEMBL29003694 0.85 F3 (0.55) ABCG2MAPTSMN1; SMN2KDM4ELMNA
SCHEMBL30274993 0.85 F3 (0.55) ABCG2MAPTSMN1; SMN2KDM4ELMNA
SCHEMBL7594006 0.82 ABCG2 (0.59) ABCG2MAPTSMN1; SMN2KDM4ELMNA
SCHEMBL7592084 0.80 ABCG2 (0.61) ABCG2MAPTPOLBALDH1A1RAB9A
SCHEMBL7591205 0.78 ABCG2 (0.61) ABCG2MAPTL3MBTL1POLBALDH1A1
SCHEMBL23781994 0.77 MAPT (0.60) MAPTSMN1; SMN2KDM4ELMNAPOLB
SCHEMBL30000178 0.77 MAPT (0.60) MAPTSMN1; SMN2KDM4ELMNAPOLB
SCHEMBL7180833 0.77 ABCG2 (0.86) ABCG2MAPTSMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1253141-A1 Substituted carbazoles as tubulin polymerization inhibitors and their use for the treatment of cancer Aventis Pharma S.A. (FR) 2002-10-30 EP disclosed